Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1605)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3722)
  2. Department of Medicine (3691)
  3. Hematologic Malignancies, Division of (3687)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (389)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (105)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (325)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3722)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I trial of targeted alpha-particle therapy using actinium-225 (Ac-225)-lintuzumab (anti-CD33) in combination with low-dose cytarabine (LDAC) for older patients with untreated acute myeloid leukemia (AML)
    Meeting Abstract

    Jurcic, J. G.; Ravandi, F.; Pagel, J. M.; Park, J. H.; Smith, B. D.; Douer, D.; Estey, E. H.; Kantarjian, H. M.; Wahl, R. L.; Earle, D.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Genomic profiling combining DNA and RNA analysis of 112 formalin-fixed paraffin-embedded diffuse large B cell lymphoma specimens identifies a high frequency of clinically relevant genomic alterations
    Meeting Abstract

    Intlekofer, A. M.; Hilden, P.; Seshan, V. E.; Copeland, A. R.; Levine, R. L.; Zelenetz, A. D.; Teruya-Feldstein, J.; Dogan, A.; Palomba, M. L.; Moskowitz, C. H.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders
    Meeting Abstract

    Hyman, D. M.; Diamond, E.; Vibat, C. R.; Hassaine, L.; Poole, J.; Patel, M.; Holley, V.; Cabrilo, G.; Lu, T. T.; Arcila, M.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Clinical utility of comprehensive profiling of genomic alterations in hematologic malignancies
    Meeting Abstract

    He, J.; Bufill, J. A.; Nahas, M. K.; Wang, K.; Young, L. E.; Knapp, K. M.; Brennan, K. W.; Donahue, A. L.; Young, G.; Ross, J. S.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Conditional loss of Dnmt3a results in myeloproliferation and liver-specific myeloid expansion
    Meeting Abstract

    Guryanova, O. A.; Lieu, Y.; Shank, K. R.; Rivera, S.; Garrett-Bakelman, F. E.; Glass, J.; Keller, M. D.; Pandey, S.; Tovbin, D.; Weinstein, A. R.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Midostaurin (PKC412) demonstrates a high rate of durable responses in patients with advanced systemic mastocytosis: Results from the fully accrued global phase 2 CPKC412D2201 trial
    Meeting Abstract

    Gotlib, J.; Kluin-Nelemans, H. C.; George, T. I.; Akin, C.; Sotlar, K.; Hermine, O.; Awan, F.; Hexner, E. O.; Mauro, M.; Sternberg, D.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Genomic analysis of serial samples from CLL patients identifies clonal events associated with disease progression
    Meeting Abstract

    Gardner, J. R.; Nahas, M.; He, J.; Aumann, S.; Gonen, M.; Patel, M.; Knapp, K. M.; Palomba, M. L.; Yelensky, R.; Donahue, A. L.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Minimal residual disease assessment by flow cytometry in AML is an independant prognostic factor even after adjusting for cytogenetic/molecular abnormalities
    Meeting Abstract

    Ganzel, C.; Sun, Z. X.; Gonen, M.; Patel, J. P.; Abdel-Wahab, O.; Fernandez, H. F.; Rowe, J. M.; Tallman, M. S.; Levine, R. L.; Paietta, E. M.
    Blood (2014)

    Fulltext@MSK | Save
  • Secondary ALL may be independent of prior cytotoxic therapy
    Meeting Abstract

    Ganzel, C.; Devlin, S. M.; Douer, D.; Stein, E. M.; Rowe, J. M.; Tallman, M. S.
    Blood (2014)

    Fulltext@MSK | Save
  • The addition of radiation therapy to initial treatment for extramedullary acute myeloid leukemia does not offer a survival benefit when added to chemotherapy
    Meeting Abstract

    Feller, F. M.; Patel, M.; Devlin, S. M.; Maloy, M.; Tallman, M. S.; Perales, M. A.; Rampal, R. K.
    Blood (2014)

    Fulltext@MSK | Save